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Abstract
Background: Thrombospondin type I domain containing 7A (THSD7A) is a novel neural protein that is known to affect
endothelial migration and vascular patterning during development. To further understand the role of THSD7A in
angiogenesis, we investigated the post-translational modification scheme of THS7DA and to reveal the underlying
mechanisms by which this protein regulates blood vessel growth.
Methodology/Principal Findings: Full-length THSD7A was overexpressed in human embryonic kidney 293T (HEK293T) cells
and was found to be membrane associated and N-glycosylated. The soluble form of THSD7A, which is released into the
cultured medium, was harvested for further angiogenic assays. We found that soluble THSD7A promotes human umbilical
vein endothelial cell (HUVEC) migration and tube formation. HUVEC sprouts and zebrafish subintestinal vessel (SIV)
angiogenic assays further revealed that soluble THSD7A increases the number of branching points of new vessels.
Interestingly, we found that soluble THSD7A increased the formation of filopodia in HUVEC. The distribution patterns of
vinculin and phosphorylated focal adhesion kinase (FAK) were also affected, which implies a role for THSD7A in focal
adhesion assembly. Moreover, soluble THSD7A increased FAK phosphorylation in HUVEC, suggesting that THSD7A is
involved in regulating cytoskeleton reorganization.
Conclusions/Significance: Taken together, our results indicate that THSD7A is a membrane-associated N-glycoprotein with
a soluble form. Soluble THSD7A promotes endothelial cell migration during angiogenesis via a FAK-dependent mechanism
and thus may be a novel neuroangiogenic factor.
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Introduction
Angiogenesis is the process of new vascular growth from pre-
existing blood vessels. It has been shown to be a critical process in
embryonic development and growth as well as in wound healing
and tumor progression. The current consensus on the molecular
mechanism of angiogenesis suggests that this vital process occurs in
several stages, which are all tightly regulated and balanced by both
pro- and anti-angiogenic factors. In the presence of pro-angiogenic
stimulation, the endothelium is induced to degrade the adjacent
extracellular matrix (ECM). This degradation allows activated
endothelial cells to migrate out of the original blood vessels. These
endothelial cells then proliferate and arrange into sprouts, which
extend toward the source of angiogenic stimulation. During
development, guidance molecules and anti-angiogenic factors act
together to ensure that such angiogenic sprouting follows a
prescribed path to connect with neighboring vessels. These sprouts
will eventually loop, stabilize and mature into functional vessels
with lumen to allow blood circulation [1–3].
During angiogenic sprouting and branch formation, endothelial
cells react to different signals and commit to distinct cellular fates.
For example, tip cells sense and respond to guidance molecules
with filopodia [4–8]. During cell migration, the filopodia at the tip
cell leading edge can sense the microenvironment and drive
directed cell migration. Previous studies have shown that integrins
located at filopodia can probe the surrounding matrix and create
‘sticky fingers’ along the leading edge. These structures, in turn,
promote the assembly of focal adhesion complexes to stabilize
protrusions and promote migration [9–10]. FAK, an important
member of focal adhesion complexes, is activated when a cell is
stimulated by clustered integrins or other growth factors. FAK can
recruit other focal adhesion components, such as vinculin and
paxillin, and establish focal adhesions [11–14].
In a previous study, we identified THSD7A as a novel
endothelial protein and found that it is preferentially expressed
in the placental vasculature. We demonstrated that carboxyl-
terminal fragments of THSD7A co-localized with aVb3 integrin
and paxillin; in addition, overexpression and knockdown of
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29000THSD7A showed that THSD7A regulates cell mobility and tube
formation in HUVEC [15]. In the other hand, zebrafish thsd7a
transcripts are detected along the ventral edge of the neural tube in
developing zebrafish, and THSD7A is required for the angiogen-
esis of intersegmental vessels (ISVs) [16]. In this study, we
demonstrate that full-length THSD7A is expressed in HUVEC
and SH-SY5Y neuroblastoma cells, and both can release a
210 kDa soluble form of the protein. We also investigate the post-
translational modification of THSD7A and the protein’s function-
al mechanism. We discovered that a soluble form of THSD7A is
released into the extracellular environment. By various in vitro and
in vivo angiogenic assays, we demonstrate that soluble THSD7A
promotes endothelial filopodia formation and focal adhesion
assembly and induces FAK-dependent signaling during angiogen-
esis. Taken together with the results of our previous study, our
findings indicate that soluble THSD7A is a potent neuroangio-
genic factor.
Materials and Methods
A detailed methods description is included in the Data S1.
Soluble THSD7A was collected from THSD7A-transfected
HEK293T cell culture medium. Cell culture medium from empty
vector-transfected HEK293T cells served as control. Experiments
were performed in primary HUVEC. Migration rate was analyzed
by transwell migration assays using polycarbonate filters (8 mm
pore size). Two-dimensional tube formation was performed on
Matrigel. Three-dimensional tube formation was performed in
type I collagen matrix and served as a measure of in vitro sprouting
ability. Analysis of branching of the zebrafish subintestinal vessel
(SIV) served as an in vivo angiogenesis assay. HUVEC adhesion,
filopodia formation, and vinculin and FAK pY397 distribution
assays were performed on collagen-coated coverslips. All of the
zebrafish use protocols in this research were reviewed and
approved by the Institutional Animal Care and Use Committee
of National Tsing Hua University (IRB Approval NO. 09507).
Results
Native THSD7A has a soluble form and is expressed by
HUVEC and SH-SY5Y cells
To investigate the role of THSD7A in angiogenesis, we purified
THSD7A-specific custom antibodies (anti-IDS2, anti-IDS9 and
anti-CTE) for further study. Commercial antibodies (anti-
sTHSD7A and anti-FLAG-tag) were also used to confirm the
results (Figure 1A). THSD7A was expressed in HUVEC lysates
based on anti-CTE antibody staining [15]. In addition, analysis of
the human THSD7A expression profile (UniGene number Hs.
120855) in the NCBI dbEST database revealed that THSD7A is
also highly expressed in tissues such as the brain and nerves.
Therefore, we compared the THSD7A protein expression patterns
in cell lysates and cultured medium from SH-SY5Y cells (a
human-derived neuroblastoma cell line) to those of HUVEC by
Western blot. As shown in Figure 1B, a 260 kDa protein was
recognized by the anti-sTHSD7A antibody in both HUVEC and
SH-SY5Y cell lysates. However, the anti-sTHSD7A antibody
Figure 1. Domain organization prediction of full-length THSD7A and epitope targeting sites. A. Based on domain prediction analysis,
THSD7A contains an extracellular signal peptide at the amino terminus, ten thrombospondin type 1 repeats, six WSXW motifs, one RGD motif, one
predicted transmembrane domain and fourteen predicted N-glycosylated sites. A FLAG-tag was fused to the carboxyl terminus of the full-length
THSD7A. The recognition sites of THSD7A-specific antibodies (sTHSD7A, IDS2, IDS9 and CTE) and the FLAG-tag are marked as <. B. Cell lysates and
cultured medium of HUVEC (H) and SH-SY5Y (S) cells were analyzed by Western blot using anti-sTHSD7A antibody.
doi:10.1371/journal.pone.0029000.g001
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(Figure 1B). These data demonstrate that native THSD7A has a
soluble form with a reduced molecular weight of ,210 kDa.
Soluble THSD7A is released from membrane-associated
N-glycosylated THSD7A
After discovering that native THSD7A has a soluble form, we
decided to investigate its post-translational modifications and
trafficking. First, we examined the subcellular distribution of
THSD7A protein using cell fractionation and Western blotting of
HEK293T cells transfected with recombinant FLAG-tagged full-
length THSD7A (Figure 2). Our data showed that all of the
THSD7A-specific and anti-FLAG-tag antibodies recognized the
same ,260 kDa band in the membrane fraction, suggesting that
full-length THSD7A is membrane associated (M lanes in Figure 2).
In these experiments, calnexin served as a plasma membrane
marker and GAPDH served as a cytoplasmic marker. Annexin V
served as both a cytoplasmic and plasma membrane marker
(Figure 2, right panel).
Interestingly, the anti-CTE and anti-FLAG-tag antibodies also
detected a ,17 kDa fragment (M lanes in Figure 2, arrow). As
described in Figure 1A, these antibodies recognized sites near the
carboxyl-terminal region of THSD7A. The results showed that
this ,17 kDa fragment was also enriched in the membrane
fraction. These data suggest that full-length THSD7A is a
membrane-associated protein with a molecular weight of
260 kDa, and it might be cleaved to release a soluble form while
leaving a 17 kDa carboxyl-terminal fragment in the cell
membrane. Next, we collected and analyzed by Western blot the
lysates and cultured medium from THSD7A-transfected
HEK293T cells. The soluble THSD7A presented in the cultured
medium had a size of ,210 kDa, which is smaller than the full-
length THSD7A (Figure 3A). This result is consistent with the
result shown in Figure 1B.
To identify post-translational modifications of THSD7A, we
conducted further analyses of THSD7A-transfected HEK293T cell
lysates and cultured medium. In silico ExPASy analysis predicted
that THSD7A would have a net molecular weight of ,186 kDa
without any post-translational modification. This weight is
significantly lower than the ,260 kDa band we observed in this
study. We hypothesized that the difference between the predicted
and apparent molecular weight of THSD7A is caused by extensive
N-glycosylation. To test this hypothesis, we treated THSD7A-
transfected HEK293T cells with tunicamycin, which is an
inhibitor of GlcNAc phosphotransferase, the enzyme responsible
for the first step of the N-glycosylation pathway (Figure 3B, upper
panel). In the absence of tunicamycin, we could again detect the
,260 kDa form of THSD7A in cell lysates and the ,210 kDa
form of soluble THSD7A in cultured medium. However, with the
addition of tunicamycin, the observed molecular weight of
THSD7A in the cell lysate was reduced to ,190 kDa, and no
soluble THSD7A could be detected in the cultured medium. N-
glycosylation of THSD7A was also demonstrated by PNGase
treatment (Figure 3B, lower panel). Furthermore, an additional
,33 kDa amino-terminal fragment was detectable using the anti-
sTHSD7A antibody in the cultured medium of transfected cells
that did not receive tunicamycin treatment (Figure 3C, left panel,
arrow head). This 33 kDa fragment was retained by a 3 kDa cutoff
Amicon concentrator, but not by a 100 kDa cutoff Amicon
concentrator (Figure 3C, right panel). Taken together, these results
indicate that soluble THSD7A is likely to be cleaved at two sites:
between the CTE and IDS9 epitopes and within the recognition
site of the anti-sTHSD7A antibody (see Figure 1A for the epitope
map).
Because THSD7A has been shown to play a role in angiogenesis
[16], we were interested in learning whether the soluble 210 kDa
form of THSD7A is responsible for regulating endothelial cells.
We therefore concentrated the THSD7A-transfected HEK293T
cell cultured medium using an Amicon concentrator (100 kDa
cutoff size) to retain the ,210 kDa soluble THSD7A (Figure 3C,
right panel, arrow) for subsequent functional assays.
Soluble THSD7A accelerates endothelial cell migration,
two-dimensional tube formation and three-dimensional
sprout formation
Based on the results of our previous study [15] and those shown
in Figure 1B, we concluded that HUVECs produce soluble
THSD7A. To determine whether this endogenous soluble
Figure 2. THSD7A is a membrane-associated protein. THSD7A-transfected HEK293T cells were homogenized and the cytosolic (C), nuclear (N)
and membrane (M) fractions were prepared as described in the materials and methods. Each fraction was subjected to Western blot with anti-
THSD7A (IDS2, IDS9, CTE), anti-FLAG-tag, anti-calnexin (plasma membrane marker), anti-annexin V (cytoplasm and plasma membrane marker) and
anti-GAPDH (cytoplasm marker) antibodies. Arrow indicates the carboxyl-terminal fragment of THSD7A.
doi:10.1371/journal.pone.0029000.g002
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immunosorbent assay to detect soluble THSD7A in the cultured
medium of HUVEC. After 48 hrs of culture, the concentration of
HUVEC-released endogenous soluble THSD7A in the cultured
medium was less than 0.1 ng/ml and below detectable limits.
Similarly, in the concentrated cell culture medium of control
vector-transfected HEK293T cells, the concentration of soluble
THSD7A was also less than 0.1 ng/ml. In contrast, the
concentration of soluble THSD7A in the cell cultured medium
of THSD7A-transfected HEK293T cells was ,75.5 ng/ml
(,360 nM); thus, endogenous soluble THSD7A should not affect
our angiogenic assays.
We used a transwell assay to determine whether soluble
THSD7A affects endothelial cell migration in vitro. As shown in
Figure 4A, HUVEC motility was not significantly different
between cells treated with 3% soluble THSD7A (,10.8 nM
soluble THSD7A final concentration) and the vector-only control.
However, when 15% soluble THSD7A (,53.9 nM soluble
THSD7A final concentration) was used, endothelial cell migration
was increased by 59% compared to the vector-only control
(Figure 4A).
We next examined the effect of soluble THSD7A on HUVEC
tube formation. We found that when 25% soluble THSD7A
(,89.8 nM soluble THSD7A final concentration) was added into
the medium, the formation of capillary-like networks on Matrigel
was significantly enhanced. Compared to the vector-only control,
the mean tube length of the HUVEC tubular network increased
by 57% in the presence of soluble THSD7A (Figure 4B). To
further confirm the angiogenic effect of soluble THSD7A, we
performed a three-dimensional tube formation assay, which
examines sprouting during angiogenesis, on HUVEC in a collagen
matrix [17–18]. Our data show that, in the presence of soluble
THSD7A, the capillary tube density was 50% higher than that of
the vector-only control group (Figure 4C, top view of the 3D
matrices). Side views of the three-dimensional endothelial
sprouting assays clearly revealed that the number and length of
endothelial sprouts increased in the presence of soluble THSD7A
(Figure 4D–E). Taken together, these data support our hypothesis
Figure 3. THSD7A is an N-glycoprotein and can release the soluble form into the extracellular environment. A. Empty vector (V)- and
THSD7A (T)-transfected HEK293T cells were analyzed by Western blot. THSD7A was detected in both cell lysates and cultured medium. GAPDH served
as a cytoplasmic marker. B. Transfected HEK293T cells were incubated in the presence (+) or absence (2) of tunicamycin. After 48 hours, cell lysates
and cultured medium were subjected to Western blot and stained with THSD7A-specific and anti-FLAG-tag antibodies (upper panel). The cell lysates
and cultured medium of THSD7A-transfected HEH293T cells were treated with (+) or without (2) PNGase and subjected to Western blot (lower panel).
C. Cultured medium from transfected HEK293T cells was concentrated by 3 kDa or 100 kDa cutoff Amicon concentrators and analyzed by Western
blot. After concentration by a 100 kDa cutoff Amicon concentrator, the 210 kDa soluble THSD7A (arrow) was retained in the concentrates and the
33 kDa amino-terminal fragment of THSD7A (arrowhead) was filtered out.
doi:10.1371/journal.pone.0029000.g003
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promote endothelial cell migration, tube formation and sprouting.
Soluble THSD7A induces angiogenic branching and
abnormal vessel patterning in zebrafish embryos
To test the angiogenic function of soluble THSD7A in vivo,
transgenic zebrafish Tg(kdr:EGFP) embryos, which have fluores-
cent vasculature, served as a model system for angiogenesis, as
previously described [19–21]. Soluble THSD7A (9.2 nl;
,0.69 ng) or control medium was injected into the zebrafish
embryo yolk at 50 hours post fertilization (hpf). After 24 hours, the
extent of development of the SIV network (Figure 5A, SIV is
outlined by a red rectangle) was imaged and analyzed. Embryos
without injection (normal) or those injected with the vector-only
medium served as controls (Figure 5C, left and middle panels).
Compared to the control groups, soluble THSD7A significantly
increased the median number of branching points per SIV
network from 1 to 3 (Figure 5B; Figure 5C, right panel). In
addition, excrescent angiogenic sprouts were observed in the
soluble THSD7A-treated SIV network, resulting in abnormal SIV
patterning (Figure 5C). These results are in agreement with our in
vitro data and validate that soluble THSD7A can also promote
angiogenesis in vivo.
Soluble THSD7A promotes filopodia formation and focal
adhesion assembly to enhance cell migration via a FAK-
involved manner
Sprouting angiogenesis occurs in several well-characterized
stages [4–5]. To determine which stage of angiogenesis is affected
by soluble THSD7A, we performed a series of assays. First, by
endothelial cell adhesion assay, we found no significant difference
between the total numbers of adherent HUVEC in the presence of
soluble THSD7A compared to the control group when cells were
plated on type I collagen- or poly-L-lysine (PLL)-coated coverslips
(Figure 6A). Thus, soluble THSD7A does not appear to affect
endothelial cell adhesion. Because soluble THSD7A could
Figure 4. Soluble THSD7A accelerates endothelial cell migration, tube formation and sprouting. A. The motility of HUVEC was evaluated
by transwell migration assay in M200 medium. HUVEC were loaded in the upper insert and soluble THSD7A or control medium were added to a 3%
or 15% final concentration into the lower chamber. B. Two-dimensional tube formation was performed in the presence or absence of soluble THSD7A
on Matrigel. C. Three-dimensional tube formation was performed in the presence or absence of soluble THSD7A on type I collagen as an assay for
sprouting. C9. Enlarged image of tubes. Bar represents 10 mm. Each experiment was repeated at least three independent times. *P,0.05 vs. vector.
D–E. Side views of the sprouting assay. Arrows indicate tubes. Bar represents 100 mm.
doi:10.1371/journal.pone.0029000.g004
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(Figure 4,5), we hypothesized that soluble THSD7A might
function in the initial steps of cell migration.
We next examined filopodia formation. We found that 20%
soluble THSD7A (,71.8 nM soluble THSD7A final concentra-
tion) significantly promoted microspike formation after HUVEC
were seeded for 50 minutes, which were seen as slender
cytoplasmic projections that extended beyond the leading edge
of lamellipodia of HUVEC from 10 to 19 projections per cell
(Figure 6B). In addition to filopodia formation, cell migration is
also affected by focal adhesion assembly [10,22]. The assembly,
disassembly and turnover rates of focal adhesions are known to
affect focal adhesion number and size. We used 20% soluble
THSD7A to examine focal adhesion number by measuring the
number of peripheral vinculin plaques; vinculin is a key adapter
protein at the focal adhesion site and is known to stabilize filopodia
[23]. After HUVEC were seeded for 50 minutes in the presence of
soluble THSD7A, the number of well-distributed peripheral
vinculin plaques (oval- or nail-shaped patterns around the attached
cell) [23] increased by two-fold compared to the vector-only
control (Figure 6C). We then investigated whether FAK, the
phosphorylation of which is known to regulate focal adhesions
during cell migration [22,24], was affected by THSD7A. In the
presence of soluble THSD7A, the number of well-distributed
peripheral FAK pY397 plaques increased by three-fold
(Figure 6D).
We then asked which cell migration signaling pathway is
affected by soluble THSD7A. As expected, the phosphorylation
level of FAK (pY397) in HUVEC increased by 93% when cells
were stimulated with 20% soluble THSD7A for 15 minutes.
Furthermore, the phosphorylation levels of Erk1/2 (pT202/R204)
and P38 (pT180/R182) also increased by 35% and 33%,
respectively. It is worth mentioning that the phosphorylation level
of Akt (pS473) was not affected by soluble THSD7A. GAPDH was
used as a loading control (Figure 6E). These results support the
hypothesis that soluble THSD7A affects filopodia formation and
focal adhesion assembly during cell migration in angiogenesis via a
FAK-dependent mechanism.
The specificity of soluble THSD7A-mediated angiogenic
effects was demonstrated by blocking the activity with
anti-sTHSD7A antibody
To demonstrate the specificity of soluble THSD7A-mediated
angiogenic effects, we used anti-sTHSD7A antibody to neutralize
the activity of soluble THSD7A. First, we performed transwell
assay to test whether the endothelial cell motility would be affected
by the addition of anti-sTHSD7A antibody. As shown in
Figure 7A, HUVEC motility in the antibody-added group was
decreased by 39% as compared to the soluble THSD7A-treated
group (which contained ,71.8 nM soluble THSD7A). This data
confirmed that soluble THSD7A promotes endothelial cell
migration specifically. Furthermore, we examined the filopodia
formation in the presence and absence of anti-sTHSD7A
antibody. Compared with the soluble THSD7A-treated group,
we found the addition of antibody decreased the number of
filopodia from 17 to 12 per cell (Figure 7B). The number of well-
distributed peripheral vinculin plaques in antibody-added group
was also significantly decreased from 22 to 15 compared with the
soluble THSD7A-treated group (Figure 7C). Taken these data
together, soluble THSD7A indeed promote angiogenesis with
significant specificity.
Discussion
In this study, we identified a soluble form of THSD7A that is
produced by cells of both endothelial and neuronal origins. This
soluble THSD7A is a N-glycoprotein that can promote
endothelial cell migration, tube formation and sprouting. Soluble
Figure 5. Soluble THSD7A increases the branching of SIVs and leads to an irregular vessel network in zebrafish. A. Images of 74 hpf
Tg(kdr:EGFP) zebrafish. The red rectangle indicates the region of the SIV network. B. The median of branch point per SIV network of 74 hpf zebrafish.
** P,0.01 vs. vector. C. Enlarged images of SIV networks. * indicates branch points. Bar represents 100 mm.
doi:10.1371/journal.pone.0029000.g005
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patterning in the zebrafish embryo. Furthermore, we determined
that these effects may be induced via regulation of filopodia
formation and focal adhesion assembly in endothelial cells.
Finally, FAK-dependent signaling pathways were shown to be
activated by soluble THSD7A, which suggests that soluble
THSD7A may be involved in the regulation of focal adhesions
during angiogenic cell migration. Addition of anti-sTHSD7A
antibody blocked the angiogenic effects of soluble THSD7A and
demonstrated its specificity. Based on these data, we have
developed a model for the potential role of soluble THSD7A in
angiogenesis (Figure 8).
Based on bioinformatic prediction, THSD7A contains several
domains and motifs that might regulate angiogenesis. For
example, THSD7A contains at least ten thrombospondin type 1
repeats (TSRs). TSRs are found in thrombospondin-1, thrombos-
pondin-2, semaphorins, UNC-5 and F-spondin, most of which are
expressed in the developing nervous system and have functional
roles in neural cell guidance and growth cone migration [25]. In
addition, THSD7A contains six extracellular WSXW motifs,
which are located in the TSRs. The WSXW motif in
thrombospondin-1 has been shown to bind and activate latent
TGF-b [26–27]. It can also interact with fibronectin and regulate
fibronectin-mediated adhesion [28] and promote cell adhesion by
Figure 6. Soluble THSD7A promotes focal adhesion assembly to enhance cell migration via FAK-dependent manner. A. Adhesion
assay performed with HUVEC in the presence and absence of soluble THSD7A on type I collagen- or PLL-coated coverslips. B. Immunostaining of
actin filaments (red) and nuclei (blue) in HUVEC. The quantitative data show the average number of filopodia per cell. C. Immunostaining of vinculin
(green) and nuclei (blue) in HUVEC. The quantitative data show the average number of peripheral vinculin plaques per cell. D. Immunostaining of p-
FAK (green) and nuclei (blue) in HUVEC. The quantitative data show the average number of peripheral p-FAK plaques per cell. Bar represents 10 mm.
*P,0.05 vs. vector. E, HUVEC lysates treated with soluble THSD7A or control medium were subjected to Western blot. Relative fold levels of p-FAK, p-
Erk1/2, p-P38, p-Akt and GAPDH are represented as the mean 6 SD. Total levels of FAK, Erk1/2, P38 and Akt served as loading controls. Each
experiment was repeated at least three independent times.
doi:10.1371/journal.pone.0029000.g006
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also critical in promoting cell spreading and FAK phosphorylation
[30]. Therefore, these functional domains/motifs in THSD7A
might enable it to regulate endothelial cell migration.
THSD7A was initially predicted to be a type I membrane
protein. Our data support this prediction and further show that
THSD7A releases part of its amino-terminal region into the
extracellular environment (Figure 2,3). The level of soluble
THSD7A in the cultured medium is reduced after blocking N-
glycosylation, suggesting that N-glycosylation is important for
THSD7A trafficking. In addition to the full-length form
(260 kDa), THSD7A appears to have three other isoforms: the
functional soluble form (210 kDa; Figure 3C, arrow), the amino-
terminal form (33 kDa; Figure 3C, arrowhead) and the mem-
brane-anchored form (17 kDa; Figure 2, arrow). Based on our
data, we suggest that full-length THSD7A is modified first by N-
glycosylation, which leads to anchoring in the plasma membrane.
A yet-to-be-identified process may cause the amino-terminal
region of THSD7A to be released into the extracellular
environment. Second, the extracellular region of THSD7A is
likely cleaved at two sites: in the region between the IDS9 and the
CTE epitopes and within the sTHSD7A epitope site, thus
generating the functional soluble form (Figure 8). In addition,
the 33 kDa amino-terminal form of THSD7A includes a region
that contains the predicted signal peptide (the first 47 amino acids
from amino terminus, ,13 kDa).
The nature of the processing scheme that releases soluble
THSD7A is an interesting question. Many proteins are modified
by proteolysis to regulate their function and activity. For example,
mature VEGF-C is cleaved and released from a VEGF-C
Figure 7. Soluble THSD7A-mediated angiogenic effects are blocked with anti-sTHSD7A antibody. A. The motility of HUVEC was
evaluated by transwell migration assay. HUVEC were loaded in the upper insert. Control medium (V) or soluble THSD7A (T) in the presence (+)o r
absence (2) of anti-sTHSD7A antibody were added to the lower chamber. Bar represents 100 mm. B. Immunostaining of actin filaments (red) and
nuclei (blue) in HUVEC treated with control medium (V) or soluble THSD7A (T) in the presence (+) or absence (2) of anti-sTHSD7A antibody. The
quantitative data show the average number of filopodia per cell. C. Immunostaining of vinculin (green) and nuclei (blue) in HUVEC treated with
control medium (V) or soluble THSD7A (T) in the presence (+) or absence (2) of anti-sTHSD7A antibody. The quantitative data show the average
number of peripheral vinculin plaques per cell. Bar represents 10 mm. *P,0.05. **P,0.01. Each experiment was repeated at least three independent
times.
doi:10.1371/journal.pone.0029000.g007
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TGF-b must be activated by cleavage of the latent TGF-b before it
can perform its diverse biological functions, including immuno-
regulation and control of proliferation [32]. The release of soluble
THSD7A is protease-dependent (Figure S1), but the specific
protease that cleaves THSD7A is still unknown.
Endothelial cell migration is a complex process containing
several steps: sensing the motile stimuli by filopodia, extending
protrusions at the leading edge, assembly of focal adhesions to
attach the protrusions to ECM, formation of stress fibers, and
recycling of the adhesive and signaling components [1,5,10,22].
During this process, endothelial tip cells are key players in sensing
angiogenic motility stimuli [5]. Previous studies have indicated
that angiogenic sprouts are enriched for migratory filopodia
[5,33]. In this study, our data demonstrate that soluble THSD7A
can promote endothelial cell migration, tube formation, sprouting
(Figure 4) and filopodia formation (Figure 6B). These results are
further supported by the observation that soluble THSD7A affects
angiogenic branching in the developing zebrafish (Figure 5). These
data all indicate that soluble THSD7A is a pro-angiogenic protein
that is important for filopodia formation during endothelial cell
migration.
The effect of soluble THSD7A appears to occur in the initial
steps of migration. Soluble THSD7A promotes filopodia forma-
tion, which is consistent with the roles of many angiogenic
proteins, such as VEGF-A and VEGF-C [33–34]. Besides
filopodia formation, we also revealed that soluble THSD7A can
promote FAK/vinculin assembly (Figure 6C–D). Assembly of the
focal adhesion complex (including FAK, vinculin, paxillin and
others) is an important step in stabilizing the adherence of
filopodial protrusions to the ECM. Focal adhesions also link the
cytoskeleton to integrins and support actin-based motility [22]. As
shown in our data, soluble THSD7A significantly increases the
phosphorylation level of FAK (Figure 6E). This is an important
step that precedes downstream signal transduction [24]. After
FAK is activated by phosphorylation, vinculin is recruited to the
FAK carboxyl-terminal focal adhesion targeting site (FAT) and
modulating cell migration, actin polymerization and mitogen-
activated protein kinase (MAPK, including Erk1/2 and P38)
signaling [12]. As shown in Figure 6E, we found the phosphor-
ylation levels of Erk1/2 and P38 were slightly increased with
soluble THSD7A treatment. MAPKs have been shown to be
stimulated by growth factors such as VEGF, fibroblast growth
factor, epidermal growth factor and platelet-derived growth factor
and are known to play an essential role in the signaling pathways
linking diverse extracellular signals to vital cellular processes [35–
37]. These growth factors activate Erk through the Ras-Raf-
MEK1/2-Erk signaling module [38], which then phosphorylates
myosin light chain kinase (MLCK) and FAK to regulate
membrane protrusion and focal adhesion dynamics [35,39]. P38,
another member of the MAPK family, is well known for its
involvement in inflammation, apoptosis and cell differentiation
[40]. P38 has been shown to be involved in cell migration through
regulation of the phosphorylation of heat shock protein 27
(HSP27) [41–42] and activation of MAPK-activated protein
kinase 2/3 [43]. Together with FAK phosphorylation, our study
indicates that Erk1/2 and P38 might also partially contribute to
the downstream cell migration signaling pathways induced by
soluble THSD7A.
It is also unclear what the potential receptor for soluble
THSD7A might be. As previous studies have indicated, integrins
are a diverse glycoprotein family that can recruit focal adhesion
components and then link to the cytoskeleton to regulate cell
migration [44–45]. Collagen, fibronectin, vitronectin, thrombos-
pondin-1, thrombin and angiostatin are reported to interact with
integrins to regulate endothelial cell migration and angiogenesis
[45–46]. There are similarities between the effects of integrins and
the effects of soluble THSD7A on endothelial cells. Thus, integrins
Figure 8. Hypothesized mechanism for the role of soluble THSD7A in angiogenesis. Soluble THSD7A is released from full-length THSD7A.
In our hypothesis, soluble THSD7A binds receptor and triggers filopodia formation and focal adhesion assembly to promote cell migration, tube
formation and sprout formation via a FAK-involved manner.
doi:10.1371/journal.pone.0029000.g008
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recognize an Arg-Gly-Asp (RGD) motif on many adhesion
proteins, including fibronectin, vitronectin, thrombospondin,
laminin and fibrinogen [47]. Interestingly, there is one RGD
motif located in the extracellular region of THSD7A (Figure 1A),
suggesting that integrins (for example, the endothelial-specific
avb3 integrin) might interact with this RGD motif on THSD7A.
Thus, it would be worthwhile to investigate the interaction
between soluble THSD7A and integrins in future studies. On the
other hand, the well-studied protein VEGFR2 and its downstream
signaling pathways are also critical in regulating angiogenesis, so
we cannot not rule out the possibility that soluble THSD7A may
interact with VEGFR2 or its co-receptors [48–49].
Data from our previous studies have illustrated that THSD7A is
a neural protein in zebrafish and is expressed in the placenta
vasculature in human. This suggests the THSD7A expression
pattern from zebrafish to human may be different, and it may play
different roles in various organs and developmental stages.
Nevertheless, the link and interplay between the membrane-
associated and soluble forms of THSD7A and their effects on
endothelial cell migration remain unclear [15–16]. In the present
study, our results support the hypothesis that THSD7A may have
a neuronal origin and that soluble THSD7A is the functional form
that promotes endothelial cell migration in vitro and in vivo. Several
neuronal-secreted axon guidance molecules, including the netrins,
slits, semaphorins and ephrins, have been implicated in endothelial
cell migration and tube formation and are now called neuroangio-
genic factors [50]. It has been shown that netrin-1 is secreted from
the ventral midline of the central nervous system, where it
regulates axon guidance [51]. However, netrin-1 treatment causes
retraction of the filopodia of endothelial tip cells and is thought to
be a repulsive vessel guidance cue [52]. Slit-2, another neural
protein, is expressed in the nervous system midline and serves as a
repulsive axon guidance cue [51]. Conversely, Slit-2 treatment
stimulates endothelial cell migration in vitro and tumor angiogen-
esis in vivo [53]. In conclusion, in light of our current findings and
previous results, we propose that THSD7A is a novel neuroangio-
genic factor.
Supporting Information
Figure S1 The release of soluble THSD7A is protease-
dependent. A. THSD7A-transfected HEK293T cells were
treated with complete protease inhibitor (C), Benzamidine (B),
Leupeptin (L) and Pepstatin A (P). Untreated cells (No) served as a
control. Cell lysates and cultured medium were subjected to
Western blot with anti-sTHSD7A antibody. GAPDH served as a
loading control. B. Two proteases, thrombin and caspase 1, are
predicted to cleave the full-length THSD7A. C. THSD7A-
transfected HEK293T cells were treated with complete protease
inhibitor (C), hirudin (H), caspase 1 inhibitor I (I) or no treatment
(No). Cell lysates and cultured medium were subjected to Western
blot with anti-sTHSD7A antibody. GAPDH served as a loading
control.
(TIF)
Data S1 Materials and Methods.
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